Business
Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma
Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n Patents extend MANF Therapeutics' exclusivity for MANF and CDNF treatment of retinal disorders in Europe into 2031Literature Watch \"Super-MANF\" article published in American Journal of Transplantation outlines microenvironment immunomodulatory role for MANF     in the retina Positive Data for MANF in Glaucoma and retinal ganglion cell repair published in the peer-reviewed scientific journal Frontiers in Molecular Neuroscience SAN FRANCISCO, Dec. 26, 2017 (GLOBE NEWSWIRE) --  Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary MANF Therapeutics, Inc. was issued patents in Europe entitled \"Method of Treatment for Retinal Disorders\" covering the therapeutic use of mesencephalic astrocyte-derived neurotrophic factor (MANF) and cerebral dopamine neurotrophic factor (CDNF) as treatments for retinal disorders, including Glaucoma. The patents extend exclusivity for the use of MANF and CDNF in the treatment of retinal disorders in Europe into 2031, and are in addition to the recent issuance of a patent from the Japan Patent Office based on the same parent patent application. Related patent applications in the US, China and other jurisdictions remain in active prosecution. Additionally, the Company announced the publication of two peer-reviewed articles outlining MANF's role in the treatment of retinal disorders in the peer-reviewed journals American Journal of Transplantation and Frontiers in Molecular Neuroscience.\n The article published in the American Journal of Transplantation entitled \"Super-MANF to the Rescue: Immunomodulation Improves Retinal Repair and Regenerative Cell Therapy\" provides insights on the strong immunomodulatory role of MANF in promoting retinal tissue repair and function, and describes a potential mechanism of action which could also explain MANF's role as a cardiomyokine that protects cardiomyocytes in response to ischemic damage in the heart. The data published in Frontiers in Molecular Neuroscience entitled \"Identification of Mesencephalic Astrocyte-Derived Neurotrophic Factor as a Novel Neuroprotective Factor for Retinal Ganglion Cells\" examined the effect of MANF on r...